Literature DB >> 12116040

Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001.

Pierre Van Damme1, Alex Vorsters.   

Abstract

In the nine years since the Global Advisory Group of the Expanded Programme on Immunisation (WHO) set 1997 as the target for integrating hepatitis B vaccination into national immunisation programmes worldwide, 129 countries have included hepatitis B vaccine as part of their routine infant or adolescent immunisation programmes (June 2001). By the end of 2002, 41 out of the 51 countries of the WHO European Region will be implementing universal hepatitis B immunisation. The rewards of effective implementation of the programmes in countries that started 10 years ago are becoming apparent; and their success offers an exemplary model for other countries. Some other countries, however, have difficulties to incorporate hepatitis B vaccine into universal childhood immunisation programmes, because of major economic constrains and the inability to procure a constant vaccine supply. The next decade will be characterised by expanded use of hepatitis B vaccines and the increasing efforts to sustain vaccine programmes and make the vaccine available to those countries and regions that cannot afford it. In Europe, as well as in the rest of the world, work still remains to be done to support and implement interventions that will bring us closer to the WHO goal and to eradicate hepatitis B. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116040     DOI: 10.1002/jmv.10091

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Hepatitis B vaccination.

Authors:  Andrew J Pollard
Journal:  BMJ       Date:  2007-11-10

Review 2.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Combined two-dose hepatitis A and B vaccine (AmBirix).

Authors:  Blair Jarvis; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  DTPa-HBV-IPV/Hib vaccine (Infanrix hexa).

Authors:  Monique P Curran; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Non-A hepatitis B virus genotypes in antenatal clinics, United Kingdom.

Authors:  Samir Dervisevic; Samreen Ijaz; Shahneila Chaudry; Richard S Tedder
Journal:  Emerg Infect Dis       Date:  2007-11       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.